相关实验视频

Updated: Sep 8, 2025

On-Chip Endothelial Inflammatory Phenotyping

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

基于系统性炎症的甘油三指数精细化用于预测新发的心血管疾病:全国多中心队列研究

Liangyu Yin¹, Lan Zhong², Yinghui Huang¹

¹Department of Nephrology, Chongqing Key Laboratory of Prevention and Treatment of Kidney Disease, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, China.

Annals of epidemiology

|August 21, 2025

概括

三糖糖 (TyG) 指数不能比其组件更好地预测心血管疾病 (CVD) 的风险. 一个新的指数,TyG-C,结合了TyG和C反应蛋白,显示了心脏病预测的改善,这表明它可能是一个优秀的生物标志物.

科学领域:

心血管医学
代谢综合征
生物标志物发现

背景情况:

通过甘油三指数 (TyG) 表示的胰岛素耐药性与心血管疾病 (CVD) 风险有关.
对TyG的预测价值和炎症标志物的影响对其对心血管疾病的预后能力尚不清楚.

研究的目的:

评估甘油三指数及其成分对新发性心血管疾病 (CVD) 的预测性能.
调查是否结合炎症标志物C反应蛋白 (CRP) 可以提高心血管疾病风险的TyG指数的预测值.

主要方法:

对7456名没有心血管疾病的参与者进行了队列研究.
使用多变量Cox模型比较了TyG,甘油三,葡萄糖,CRP,TyC指数和TyG- C指数的预测能力.
根据TyG-C三位数估计了心血管疾病事件的危险比率.

主要成果:

甘油三糖 (TyG) 指数与心血管疾病和冠心病 (CHD) 的甘油三糖和中风的甘油三糖具有相似的预测性能.
与TyG和其他指数相比,新型TyG- C指数显示出对心血管疾病的优异预测能力.
较高的TyG- C三位数与心血管疾病,冠状动脉疾病和中风的风险增加有单调的关联,随着年龄的增长,这种关联会减弱.

结论:

与其单个成分相比,甘油三糖 (TyG) 指数无法更好地预测新发性心血管疾病.
包含C-反应蛋白的TyG-C指数显示为评估心血管疾病风险的更有效生物标志物.

关键词:

一种C反应蛋白心血管疾病慢性心脏病一次中风三甘油糖指数

更多相关视频

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

相关概念视频

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Inflammation

Inflammation

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...